Interactions of the narcotic l-α-acetylmethadol with human cardiac K+ channels

European Journal of Pharmacology

Volumn 458, Issue 1-2, 2003, Pages 25-29

  Kang, Jiesheng ^a   Chen, Xiao Liang ^a   Wang, Hongge ^a   Rampe, David ^a  

^a SANOFI   (France)

Author keywords

HERG channel; K+ channel; L acetylmethadol; QT prolongation; Torsades de pointes

Indexed keywords

DRUG METABOLITE; LEVACETYLMETHADOL; NORACYMETHADOL; POTASSIUM CHANNEL; PROTEIN HERG; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; HEART ELECTROPHYSIOLOGY; HEART MUSCLE FIBER MEMBRANE POTENTIAL; HEART PROARRHYTHMIA; IC 50; MOLECULAR CLONING; NONHUMAN; OPIATE ADDICTION; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL;

ANIMALS; CATION TRANSPORT PROTEINS; CHO CELLS; CRICETINAE; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; MEMBRANE POTENTIALS; METHADYL ACETATE; NARCOTICS; POTASSIUM CHANNELS; POTASSIUM CHANNELS, VOLTAGE-GATED; TRANS-ACTIVATORS;

EID: 0037218872     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02700-0     Document Type: Article

References (18)

1. Ks cardiac potassium current. Nature. 384:1996;78-80.
2. Ben-David J., Zipes D.P. Torsades de pointes and proarrhythmia. Lancet. 341:1993;1578-1582.
3. Brown A.M., Rampe D. Drug-induced long QT syndrome: is HERG the root of all evil? Pharm. News. 7:2000;15-20.
4. Deamer R.L., Wilson D.R., Clark D.S., Prichard J.G. Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM®). J. Addict. Dis. 20:2001;7-14.
5. + channel in ventricular muscle. A molecular correlate for the transient outward current. Circ. Res. 79:1996;659-668.
6. Eissenberg T., Bigelow G.E., Strain E.C., Walsh S.L., Brooner R.K., Stitzer M.L., Johnson R.E. Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence. JAMA. 277:1997;1945-1951.
7. Finkle B.S., Jennison T.A., Chinn D.M., Ling W., Holmes E.D. Plasma and urine disposition of l-α-acetylmethadol and its principle metabolites in man. J. Anal. Toxicol. 6:1982;100-105.
8. Henderson G.L., Wilson B.K., Lau D.H.M. Plasma l-α-acetylmethadol (LAAM) after acute and chronic administration. Clin. Pharmacol. Ther. 21:1976;16-25.
9. Kaiko R.F., Inturrisi C.E. Disposition of acetylmethadol in relation to pharmacologic action. Clin. Pharmacol. Ther. 18:1975;96-103.
10. Kang J., Chen X.-L., Wang L., Rampe D. Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG. J. Pharmacol. Exp. Ther. 299:2001;290-296.
11. Kongsamut S., Kang J., Chen X.-L., Roehr J., Rampe D. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur. J. Pharmacol. 450:2002;37-41.
12. Moody D.E., Alburges M.E., Parker R.J., Collins J.M., Strong J.M. The involvement of cytochrome P450 3A4 in the N-demethylation of l-alpha-acetylmethadol (LAAM), norLAAM and methadone. Drug Metab. Dispos. 25:1997;1347-1353.
13. O'Leary M.E. Inhibition of human ether-a-go-go potassium channels by cocaine. Mol. Pharmacol. 59:2001;269-277.
14. Rampe D., Roy M.-L., Dennis A., Brown A.M. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett. 417:1997;28-32.
15. Kr potassium channel. Cell. 81:1995;299-307.
16. Ks potassium channel. Nature. 384:1996;80-83.
17. Schwetz B.A. Labeling changes for Orlaam. JAMA. 285:2001;2705.
18. Walsh S.L., Johnson R.E., Cone E.J., Bigelow G.E. Intravenous and oral l-α-acetylmethadol: pharmacodynamics and pharmacokinetics in humans. J. Pharmacol. Exp. Ther. 285:1998;71-82.